These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 30729869)

  • 1. Drug repositioning in pulmonary arterial hypertension: challenges and opportunities.
    Grinnan D; Trankle C; Andruska A; Bloom B; Spiekerkoetter E
    Pulm Circ; 2019; 9(1):2045894019832226. PubMed ID: 30729869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Network module-based drug repositioning for pulmonary arterial hypertension.
    Wang RS; Loscalzo J
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):994-1005. PubMed ID: 34132494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhalation of repurposed drugs to treat pulmonary hypertension.
    Gessler T
    Adv Drug Deliv Rev; 2018 Aug; 133():34-44. PubMed ID: 29886070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions.
    Polamreddy P; Gattu N
    Drug Discov Today; 2019 Mar; 24(3):789-795. PubMed ID: 30513339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing: progress, challenges and recommendations.
    Pushpakom S; Iorio F; Eyers PA; Escott KJ; Hopper S; Wells A; Doig A; Guilliams T; Latimer J; McNamee C; Norris A; Sanseau P; Cavalla D; Pirmohamed M
    Nat Rev Drug Discov; 2019 Jan; 18(1):41-58. PubMed ID: 30310233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapeutic approaches for pulmonary arterial hypertension: Unique molecular targets to site-specific drug delivery.
    Vaidya B; Gupta V
    J Control Release; 2015 Aug; 211():118-33. PubMed ID: 26036906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of platelet-derived growth factor signaling in pulmonary arterial hypertension.
    Berghausen E; ten Freyhaus H; Rosenkranz S
    Handb Exp Pharmacol; 2013; 218():381-408. PubMed ID: 24092349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities.
    Badlam JB; Bull TM
    Ther Adv Chronic Dis; 2017 Feb; 8(2-3):47-64. PubMed ID: 28348727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.
    Zolty R
    J Exp Pharmacol; 2021; 13():817-857. PubMed ID: 34429666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes.
    Beckmann T; Shelley P; Patel D; Vorla M; Kalra DK
    Pharmaceuticals (Basel); 2022 Oct; 15(10):. PubMed ID: 36297354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: An Immunological Perspective.
    Koudstaal T; Boomars KA; Kool M
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32092864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are anticoagulants still indicated in pulmonary arterial hypertension?
    Olschewski H; Rich S
    Pulm Circ; 2018; 8(4):2045894018807681. PubMed ID: 30284508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
    Orriols M; Gomez-Puerto MC; Ten Dijke P
    Cell Mol Life Sci; 2017 Aug; 74(16):2979-2995. PubMed ID: 28447104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of pulmonary arterial hypertension: A review of drugs available for advanced therapy.
    Wilken E; Bennji S; Symons G; Williams PG; Allwood B
    Afr J Thorac Crit Care Med; 2019; 25(1):. PubMed ID: 34286246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current drug targets and future therapy of pulmonary arterial hypertension.
    Ito T; Ozawa K; Shimada K
    Curr Med Chem; 2007; 14(6):719-33. PubMed ID: 17346158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptosis-based therapy to treat pulmonary arterial hypertension.
    Suzuki YJ; Ibrahim YF; Shults NV
    J Rare Dis Res Treat; 2016; 1(2):17-24. PubMed ID: 27819072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs.
    Parisi D; Adasme MF; Sveshnikova A; Bolz SN; Moreau Y; Schroeder M
    Comput Struct Biotechnol J; 2020; 18():1043-1055. PubMed ID: 32419905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel approaches to pulmonary arterial hypertension drug discovery.
    Sung YK; Yuan K; de Jesus Perez VA
    Expert Opin Drug Discov; 2016; 11(4):407-14. PubMed ID: 26901465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Medical and surgical management for pulmonary arterial hypertension.
    Idrees MM; Swiston J; Nizami I; Al Dalaan A; Levy RD
    Ann Thorac Med; 2014 Jul; 9(Suppl 1):S79-91. PubMed ID: 25077002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.